In an­oth­er try at lung can­cer niche, J&J nabs a po­ten­tial Tagris­so ri­val for $50M-plus

Weeks af­ter bow­ing out of a bil­lion-dol­lar deal with Aduro Biotech, J&J is back to the draw­ing board with an­oth­er on­col­o­gy li­cens­ing pact that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.